Canakinumab
Anti-IL-1beta monoclonal antibody
- Response rate
- 67.5% complete response
- Onset
- Days-weeks
- Route
- SC 150mg every 4-8 weeks
- Line
- 2nd
- IgM effect
- Normalises SAA/CRP
Evidence summary
FDA and EMA approved for FMF. Longer dosing interval than anakinra (every 4-8 weeks vs daily). Reduced attacks from 8.3 to 1.56 per 24 weeks (P<0.001) in one cohort. Effective after colchicine and/or anakinra failure. Preferred by 72.2% of clinicians for colchicine-resistant FMF in multinational survey.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Central effector cytokine | Elevated | established |